Risk Factors Update Summary
- Accumulated deficit increased from $151 million to $160 million as of December 31, 2023.
- Cash decreased from $14.5 million to $5.2 million as of December 31, 2023.
- Raised $18.0 million in gross proceeds from an equity financing in August 2022.
- Increased expenses expected as trials of PoNS Therapy continue and regulatory approvals are pursued.
- Revenue decreased from $0.8 million to $0.6 million for the year ended December 31, 2023.
- CE certification obtained for commercial distribution in Europe for the PoNS device.
- Revenue generation uncertainty due to global macroeconomic instability and geopolitical conflicts.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1610853&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.